Darwin Global Management, Ltd. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001839209

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 5 positions · Total reported value $3.76B · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 50.0% · 0 new · 2 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): -16.0% · vs SPY -30.8% · Prev Value $3.77B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Darwin Global Management, Ltd. disclosed 5 equity positions with a combined reported value of $3.76B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RVMD ($2.05B), INSM ($673.60M), BLTE ($456.59M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Darwin Global Management, Ltd. opened 0 new positions, trimmed 2 and fully exited 1, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 83% of names.

Of the 1 positions fully exited versus the prior quarter, the largest were DNTH ($1.46M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • DNTH DIANTHUS THERAPEUTICS INC · prev qtr: $1.46M

Insider Transactions (Form 4)

Latest Darwin Global Management, Ltd. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Darwin Global Management, Ltd. is an SEC-registered 13F filer. As of Q2 2026 it reported 5 US equity positions with a combined value of $3.76B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 5 positions · $3.76B reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 54.5%
  • Average position size: $752.05M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 added, 2 reduced, 1 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Darwin Global Management fund appears to have a bullish stance on the healthcare sector, as evidenced by the significant increase in positions within this sector and the addition of new healthcare stocks. However, there are some adjustments in existing positions, indicating a selective approach rather than a blanket bullish sentiment across all healthcare investments. 2. Key Moves: - Added: Revolution Medicines (RVMD) by 380.8% (from 2,211,018 to 10,629,822 shares), suggesting a strong belief in the company's potential. - Reduced: InSMed Inc. (INSM) by 61.7% (from 16,805,184 to 6,431,163 shares), which might reflect a shift in the fund's focus within the healthcare sector. - Added: Belite Bio Inc. (BLTE) by 0.6% (from 3,057,412 to 3,077,219 shares), indicating a slight increase in confidence. - Added: Abivax SA (ABVX) by 4.4% (from 3,468,657 to 3,621,583 shares), showing a modest but positive outlook. - Reduced: Roivant Sciences Ltd. (ROIV) by 0.7% (from 6,797,300 to 6,747,300 shares), which could mean a slight pullback in the company's prospects. 3. Portfolio Structure: The portfolio is active, with a sector bias towards healthcare. The fund's risk appetite seems moderate, as it has diversified its holdings within the healthcare sector rather than focusing on a few stocks. There's a balance between increasing and reducing positions in various companies, indicating a strategic approach to risk management. 4. Per-Holding One-Liner: - RVMD: Revolution Medicines Inc. is focused on developing treatments for genetically defined cancers and rare diseases. 'Verified' - INSM: InSMed Inc. is a biopharmaceutical company focused on developing therapies for neurological and ophthalmic diseases. 'Verified' - BLTE: Belite Bio Inc. is a clinical-stage biopharmaceutical company developing treatments for orphan diseases. 'Verified' - ABVX: Abivax SA is a biopharmaceutical company that focuses on the development of treatments for autoimmune and viral diseases. 'Verified' - ROIV: Roivant Sciences Ltd. is a global biopharmaceutical company that develops and commercializes products across a broad range of therapeutic areas. 'Verified' 5. One-Sentence Style Summary: Darwin Global Management increased its healthcare sector exposure, particularly in Revolution Medicines, while trimming back on InSMed Inc., reflecting a selective approach to growth opportunities within the healthcare industry.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 10.63M $2.05B 54.45%
54.45%
Add
2 6.43M $673.60M 17.91%
17.91%
Reduce
3 3.08M $456.59M 12.14%
12.14%
Add
4 3.62M $348.22M 9.26%
9.26%
Add
5 6.75M $234.33M 6.23%
6.23%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 83% R 100% F1 91% (modelled on 2026-Q1; 5/10 hit)

Low-confidence forecast This fund replaces about 47% of its Top-10 each quarter and backtests at F1 54% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 55% · recall 57% · F1 54% · avg rank error 4.3 · Top-10 turnover 47%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 38% 30% 33% AMAM · TGTX · MLTX · CYTK · KROS · PCVX · SWTX · NUVL PCVX · NUVL · KROS · BHVN · ALPN · BEAM · APGE · XNCR · SYRE · ELEV
2024-Q2 40% 44% 42% PCVX · NUVL · KROS · BHVN · ALPN · BEAM · APGE · XNCR · SYRE · ELEV CYTK · INSM · PCVX · GERN · KROS · CRBP · SYRE · RNAM · ELEV
2024-Q3 44% 80% 57% CYTK · INSM · PCVX · GERN · KROS · CRBP · SYRE · RNAM · ELEV INSM · PCVX · GERN · KROS · SMMT
2024-Q4 60% 50% 55% INSM · PCVX · GERN · KROS · SMMT INSM · JAZZ · VRNA · GERN · KROS · NRIX
2025-Q1 33% 67% 44% INSM · JAZZ · VRNA · GERN · KROS · NRIX INSM · VRNA · ALLO
2025-Q2 100% 60% 75% INSM · VRNA · ALLO INSM · VRNA · CDTX · MRUS · ALLO
2025-Q3 40% 40% 40% INSM · VRNA · CDTX · MRUS · ALLO INSM · UTHR · ABVX · CDTX · QURE
2025-Q4 60% 50% 55% INSM · UTHR · ABVX · CDTX · QURE INSM · BLTE · ABVX · CDTX · WVE · CAPR
2026-Q1 50% 50% 50% INSM · BLTE · ABVX · CDTX · WVE · CAPR INSM · BLTE · ABVX · RVMD · ROIV · DNTH
2026-Q2 ★ 83% 100% 91% INSM · BLTE · ABVX · RVMD · ROIV · DNTH RVMD · INSM · BLTE · ABVX · ROIV

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Darwin Global Management, Ltd. buy in 2026-Q2?

In its 2026-Q2 13F filing, Darwin Global Management, Ltd. reported 5 equity positions worth $3.76B in aggregate; its largest disclosed positions were RVMD ($2.05B), INSM ($673.60M), BLTE ($456.59M).

How large is Darwin Global Management, Ltd.'s portfolio?

Darwin Global Management, Ltd. reported $3.76B of long equity holdings across 5 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Darwin Global Management, Ltd.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/darwin-global-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →